Proposed treatment guidance on new anticancer agents for the treatment of hepatocellular carcinoma, 2010 up date
-
- Kaneko Shuichi
- The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
-
- Furuse Junji
- The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
-
- Kudo Masatoshi
- The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
-
- Ikeda Kenji
- The Committee of Proposed Treatment Guidance on New Anticancer Agents for the Treatment of Hepatocellular Carcinoma
-
- Honda Masao
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Nakamoto Yasunari
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Onji Morikazu
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Shiota Goshi
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Yokosuka Osamu
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Sakaida Isao
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Takehara Tetsuo
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Ueno Yoshiyuki
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Hiroishi Kazumasa
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Nishiguchi Shuhei
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Moriwaki Hisataka
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Yamamoto Kazuhide
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Sata Michio
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Obi Shuntaro
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Miyayama Shiro
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
-
- Imai Yukinori
- Development Group on Management of New Anticancer Agents for Hepatocellular Carcinoma
Bibliographic Information
- Other Title
-
- 肝がんに対する新規抗がん剤使用に関する指針 2010年度版 平成22年度厚生労働科学研究費補助金(肝炎等克服緊急対策研究事業)
- カン ガン ニ タイスル シンキ コウガンザイ シヨウ ニ カンスル シシン 2010ネンドバン ヘイセイ 22ネンド コウセイ ロウドウ カガク ケンキュウヒ ホジョキン カンエン トウ コクフク キンキュウ タイサク ケンキュウ ジギョウ
Search this article
Abstract
The Research Team on New Cancer Therapies, funded by a Ministry of Health, Labour and Welfare (MHLW) Grant-in-Aid for Scientific Research (Emergency Research Project to Conquer Hepatitis), summarized the usage performance and side-effect frequency of two drugs in trials conducted on patients with progressive hepatocellular carcinoma at 16 participating facilities until December 22, 2010. The team examined 264 cases in which sorafenib was used, and 535 cases in which miriplatin was used for treatment. To more quickly ascertain views on the current and appropriate use of anticancer agent, and to move toward their use in actual treatment scenarios, the researchers, citing published articles, academic presentations, and reports by companies, presented the problems that arose during treatment as clinical questions, presented recommendations in response to each clinical question regarding the kind of care and treatment that should be given, and compiled guidelines in which their reasons for issuing those recommendations were presented as scientific statements.<br>
Journal
-
- Kanzo
-
Kanzo 52 (8), 532-551, 2011
The Japan Society of Hepatology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679770762240
-
- NII Article ID
- 10029526628
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 11240468
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed